Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

KMI announces strategic distribution agreement with Mobility to market stroke therapy devices

Kinetic Muscles Inc., a leading developer of stroke therapy technology, today announced a strategic distribution agreement with Mobility Research, also of Tempe, that will allow Mobility to market KMI’s products in specific international markets.

23 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Competitive bidding program for durable medical equipment: Myths and realities

Medicare has been touting the merits of the "competitive" bidding program for durable, or home medical equipment and services (HME) to convince Congress that the program is good for seniors. Unfortunately, proponents have conveyed misleading information and cherry-picked facts that exaggerate the benefits and ignore the severe shortcomings of the program.

18 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

16 Mar 2010

ThinkFirst Brain Day program for school children

Today marks the start of international Brain Awareness Week, a unique partnership of more than 1,700 organizations in 57 countries. In Canada, ThinkFirst Canada is teaching children to use their brains to protect their bodies by presenting the ThinkFirst Brain Day program in schools this spring.

16 Mar 2010

Bioness announces two agreements to distribute new devices for patients with neurological impairment

Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.

11 Mar 2010

Homecare advocates discuss the value and cost-effectiveness of home-based care

More than 250 providers of home medical equipment and services from across the U.S. met with members of Congress this week during the American Association for Homecare's Washington Legislative Conference.

6 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

IOS Press is pleased to announce the 20th anniversary of the peer-reviewed journal Restorative Neurology and Neuroscience. Since founded in 1989 by pioneering neuroscientist Donald G. Stein, RNN has focused on the emerging field of brain plasticity, repair and rehabilitation and has published not only numerous original scientific publications, but also review papers in basic research (animal experiments, in vitro studies) and in the clinical sciences.

25 Feb 2010

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in the Feb. 24 issue of the Journal of Neuroscience.

25 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Neuralstem raises $5.25M, also receives NYSE Amex compliance notice

Neuralstem, Inc. announced today that it has raised a total of $5,228,000 since the beginning of the year, comprised of a previously disclosed $1.5 million private placement of 646,551 common shares at $2.32, priced at a 30 percent premium over the market on the closing, and approximately $3.7 million from warrant exercises.

19 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Study shows significant decline in hockey-related spinal injuries

The past decade has seen a significant reduction in the number and severity of spinal cord injuries in Canadian ice hockey, reports a study in the Clinical Journal of Sport Medicine.

30 Jan 2010

Health organizations urge Congress to protect Medicare beneficiaries' access to critical rehabilitative services

A coalition of organizations representing consumers, health professionals and providers recently sent a letter to Congressional Leadership, calling for the immediate reinstatement of the exceptions process for Medicare Part B outpatient therapy services. Without such efforts, thousands of Medicare beneficiaries will exceed arbitrary limitations on physical therapy, occupational therapy, and speech-language pathology services.

28 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Spinal Cord Injury News and Research

Further Reading

KMI announces strategic distribution agreement with Mobility to market stroke therapy devices

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Competitive bidding program for durable medical equipment: Myths and realities

Reversal of aging in normal human cells

BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

ThinkFirst Brain Day program for school children

Bioness announces two agreements to distribute new devices for patients with neurological impairment

Homecare advocates discuss the value and cost-effectiveness of home-based care

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Neuralstem raises $5.25M, also receives NYSE Amex compliance notice

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Study shows significant decline in hockey-related spinal injuries

Health organizations urge Congress to protect Medicare beneficiaries' access to critical rehabilitative services

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News